<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5824">
  <stage>Registered</stage>
  <submitdate>10/11/2015</submitdate>
  <approvaldate>10/11/2015</approvaldate>
  <nctid>NCT02603120</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed</studytitle>
    <scientifictitle>A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-004025-14</secondaryid>
    <secondaryid>GS-US-380-1844</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV-1 Infection</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABC/DTG/3TC
Treatment: drugs - B/F/TAF
Treatment: drugs - ABC/DTG/3TC Placebo
Treatment: drugs - B/F/TAF Placebo

Experimental: Blinded Phase: B/F/TAF - B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks

Active Comparator: Blinded Phase: ABC/DTG/3TC - ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks

Experimental: Open-Label Phase - At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.


Treatment: drugs: ABC/DTG/3TC
600/50/300 mg FDC tablets administered orally once daily without regard to food

Treatment: drugs: B/F/TAF
50/200/25 mg FDC tablets administered orally once daily without regard to food

Treatment: drugs: ABC/DTG/3TC Placebo
Tablets administered orally once daily without regard to food

Treatment: drugs: B/F/TAF Placebo
Tablets administered orally once daily without regard to food

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of participants with virologic failure (HIV-1 RNA = 50 copies/mL) as defined by the modified US FDA-defined snapshot algorithm</outcome>
      <timepoint>Week 48</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL as defined by the US FDA-defined snapshot algorithm</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in CD4+ cell count at Week 48</outcome>
      <timepoint>Baseline and Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage change from baseline in hip and spine bone mineral density (BMD) at Week 48</outcome>
      <timepoint>Baseline and Week 48</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Estimated glomerular filtration rate = 50 mL/min (= 0.83 mL/sec)

          -  Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC for
             = 3 months prior to the screening visit

          -  HIV RNA &lt; 50 copies/mL at the screening visit

          -  Currently on a stable regimen for = 3 months preceding the screening visit with
             documented plasma HIV-1 RNA &lt; 50 copies/mL for = 3 months preceding the screening
             visit (or undetectable HIV-1 RNA level according to the local assay being used if the
             limit of detection is = 50 copies/mL).

          -  Have no documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV),
             DTG, ABC or 3TC

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Current alcohol or substance use judged by the Investigator to potentially interfere
             with subject study compliance

          -  Active tuberculosis infection

          -  Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, or
             variceal bleeding)

          -  Females who are pregnant

          -  Females who are breastfeeding

          -  Acute hepatitis in the 30 days prior to study entry

          -  Chronic Hepatitis B Virus (HBV) infection

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>11/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>567</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital> - Sydney</hospital>
    <postcode>2010 NSW - Sydney</postcode>
    <postcode>2010 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Ghent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>NICE Cedex 03</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris cedex 20</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago de Compostela</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Brighton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and
      abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of
      abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of
      bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC
      as the FDC ABC/DTG/3TC in virologically suppressed HIV-1 infected adults.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02603120</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>